The global Cancer Biological Therapy Market was valued at around US$ 90.9 Billion at the end of 2021. The market is projected to register a 7.8 % CAGR and top a valuation of US$ 209.8 Billion by 2032.
In the upcoming years, the global market for cancer biological therapies is anticipated to grow at a crucial rate. Effective government policies in developed countries for cancer therapy are the main factor that is projected to drive the global market for cancer biological therapies.
Cancer biological therapy is a sophisticated method of cancer treatment that makes use of a live organism. These life forms are either produced in a lab to cure a cancer infection or obtained from living cells. There are many different kinds of biological treatments, some of which include monoclonal antibodies, interleukins, interferon, and vaccinations. The therapy essentially combats cancer by directly or indirectly making use of the body's immune system. The global market for cancer biological therapy is expected to grow as a result of the rising incidence of cancer cases and the number of specialized cancer treatment facilities around the world.
In economically developed nations, 58% of all newly diagnosed cancer cases happen in patients 65 years of age or older, compared to 40% in developing nations, says globocan. Cancer is the third major cause of mortality in low- and middle-income countries and the second leading cause of death in high-income countries when countries are categorized according to income.
| Attributes | Details |
|---|---|
| Cancer biological therapy market value in 2021 | US$ 90.9 Billion |
| Cancer biological therapy market value in 2032 | US$ 209.8 Billion |
| Cancer biological therapy market CAGR (2022 to 2032) | 7.8 % |
Growing demand for cancer biological therapy market due to increasing education and awareness in the upcoming few years, it is anticipated that the global market for cancer biological therapies would expand quickly. This is attributable to an increase in funding for advanced therapeutic research and development by several public and commercial organizations. Furthermore, the global market for cancer biological therapies is projected to be driven by favorable government policies in industrialized nations for the treatment of cancer.
The rising prevalence of diseases is projected to increase the need for treatment and fuel industrial expansion. Additionally, increased exposure to external carcinogens as well as rising alcohol and tobacco use will raise the risk of getting cancer which will drive up market demand for cancer biological therapy.
The World Health Organization (WHO) has reported that the burden of cancer is rapidly rising globally, increasing the need for cancer biological therapy. The market has grown because of the world's aging population. Since biological therapy for the treatment of cancer uses a targeted approach without doing much harm to the nearby healthy cells in the body, it has become more popular than other chemotherapies on the market.
The Cancer Biological Therapy Market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
During the projection period, North America is anticipated to have a significant market share for cancer biological therapies worldwide. This is attributable to the region's extensive player base and well-developed healthcare system.
During the projection period, substantial growth in the Asia Pacific market for cancer biological therapies is anticipated. The region's cancer biological therapy market is expected to develop faster than average due to the rising cancer burden, the vast patient pool, and improvements in cancer therapy. Furthermore, the market for cancer biological therapy in the Asia Pacific is anticipated to grow over the next years as a result of fast-increasing molecular biology techniques, the complexity of health care, technology improvements, and creative approaches.
F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., GSK plc, Novartis AG, Bayer AG, Lilly, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Lupin, Endo Pharmaceuticals plc, Zydus Group, Bausch Health Companies Inc., among others.
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 7.8 % from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Million, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segment Covered | By Therapy Type, By Route of Administration, By Cancer Type, By End User, By Region |
| Region Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Players | F. Hoffmann-La Roche Ltd.; Mylan N.V; Teva Pharmaceutical Industries Ltd.; Sanofi, Pfizer Inc.; GSK plc; Novartis AG; Bayer AG; Lilly; Merck & Co., Inc.; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma; Lupin; Endo Pharmaceuticals plc; Zydus Group; Bausch Health Companies Inc.; Others |
| Customization | Available Upon Request |
The market is likely to register a CAGR of 5.5% through 2032.
The market is currently valued at US$ 54.01 Billion in 2022.
The market is likely to grow to a valuation of US$ 92.26 Billion by 2032.
Asia Pacific is likely to be a leading market during the forecast period.
Explore Similar Insights
Cancer Biological Therapy Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
